Actively Recruiting
Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
Led by M.D. Anderson Cancer Center · Updated on 2026-04-15
80
Participants Needed
1
Research Sites
244 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The EXPAND trial (EXtending outcomes for PAncreas cancer patients with Nominal oligometastatic Disease) is a randomized phase III trial assessing the efficacy of MDT to improve PFS and OS for patients with oligometastatic pancreatic ductal adenocarcinoma (PDAC).
CONDITIONS
Official Title
Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 or older
- Histologically or cytologically confirmed pancreatic ductal adenocarcinoma
- ECOG performance status 2 or less
- Eligible for metastasis-directed therapy (MDT) including radiation, surgery, ablation, or embolization to all disease sites
- Between one and five distant metastatic lesions, counting nodal lesions as specified
- Baseline imaging within 4 weeks prior to randomization showing oligometastatic disease
- For females of childbearing potential: not breastfeeding, negative pregnancy test, and agreement to use effective contraception
- For sexually active non-sterilized males with female partners of childbearing potential: agreement to use effective contraception
- Adequate organ function as defined by screening labs within 4 weeks prior to enrollment
You will not qualify if you...
- Presence of metastatic effusion such as pleural effusion or ascites (except very small effusions)
- Leptomeningeal disease
- Peritoneal carcinomatosis
- Cognitive impairment preventing informed consent
- Any condition interfering with study treatment or result interpretation
- Diffuse bone marrow involvement without bone metastasis
- More than four prior lines of systemic therapy for metastatic disease
- Active scleroderma, lupus, or other rheumatologic diseases precluding safe radiotherapy (unless non-radiotherapy MDT planned)
- Psychiatric or substance abuse disorders interfering with participation
- Concurrent other primary malignancy posing substantial risk to life as judged by physicians
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
MD Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
E
Ethan Ludmir, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here